Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.67 - $2.55 $123,905 - $189,197
-74,195 Reduced 39.87%
111,906 $231 Million
Q4 2023

Feb 13, 2024

BUY
$1.67 - $2.49 $240,480 - $358,560
144,000 Added 342.03%
186,101 $396 Million
Q3 2023

Nov 13, 2023

BUY
$1.97 - $2.91 $82,938 - $122,513
42,101 New
42,101 $82.9 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $333M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Pale Fire Capital Se Portfolio

Follow Pale Fire Capital Se and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pale Fire Capital Se, based on Form 13F filings with the SEC.

News

Stay updated on Pale Fire Capital Se with notifications on news.